Remove Biopharma Remove Patients Remove Prescription
article thumbnail

Access solutions: the missing link that prevents biopharma innovation from reaching patients

pharmaphorum

Science has taken a vertical growth trajectory, yet such innovations are, at best, slow to reach the patients in need. We believe that innovation in patient access models is the necessary catalyst to aid patients in starting on and staying on the therapies they need to improve their lives.

article thumbnail

Ipsen beefs up in oncology, buying US biopharma Epizyme

pharmaphorum

The bolt-on deal comes shortly after Ipsen announced plans to sell its consumer health business for around €350 million, leaving it as a pure-play prescription pharma operating in the cancer, rare diseases and neuroscience categories. The post Ipsen beefs up in oncology, buying US biopharma Epizyme appeared first on.

Biopharma 110
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

An Upcoming White House Decision May Jeopardize Americans’ Access to Life-Saving Drugs

MedCity News

The White House might soon finalize a rule that will either save or cost patients billions of dollars in prescription drug costs. The rule concerns “copay accumulators,” which are programs health plans use to prevent copay assistance from counting toward patients’ deductibles or out-of-pocket maximums.

article thumbnail

Navigating the Challenges of Biopharma Product Launches: A Blueprint for Success

PM360

Embarking on the journey from product development to market success in the biopharma industry is no small feat. The landscape is highly competitive with new prescription medications launching worldwide each year. However, this journey is fraught with challenges as revealed by an in-depth analysis.

article thumbnail

An Outlook on Data-Powered Patient Support

Pharmaceutical Commerce

Matt Wolf, president of biopharma services, Cencora, discusses the importance of partnership in helping to combat prescription drug abandonment and non-adherence.

article thumbnail

Meeting the needs of rare disease patients: Improved access to specialty pharmaceuticals, gene and cell therapies

MedCity News

Specialty carve outs that move specialty drugs away from traditional prescription drug management to a pharmacy benefit administrator (PBA) or specialty administrator will continue and likely to provide cost savings.

article thumbnail

Consumer Choice Is the Key to Solving Our Massive Prescription Drugs Non-Adherence Problem

MedCity News

What we need to overcome adherence challenges is a digitally enabled marketplace of options that can be personalized to the patient and the context of their specific condition, pharmacy preference and ability to pay.